Divergent Myeloid Transformation in Genetically Confirmed Chediak– Higashi Syndrome–Associated Hemophagocytic Lymphohistiocytosis: A Two-Case Series and Literature Review

Some people are born with a rare genetic condition that leaves their immune system in a state of constant, dangerous alarm. This disorder, known as Chediak–Higashi syndrome, stems from a flaw in the tiny transport systems inside their cells. Normally, immune cells use these systems to move specialized weapons to the surface where they can destroy invaders. In this syndrome, the transport trucks break down, causing the weapons to pile up inside the cell and form giant, abnormal clumps. Because the immune cells cannot fire their weapons effectively, the body struggles to fight infections. Worse, the immune system often turns on itself, launching a massive, uncontrolled attack on the body's own tissues. This runaway inflammation, called hemophagocytic lymphohistiocytosis, is a life-threatening emergency that causes high fevers, severe fatigue, and the destruction of blood cells.

For decades, doctors have known that treating this runaway inflammation is critical, but the path to recovery has been fraught with its own dangers. The standard treatment involves powerful drugs designed to calm the immune system, yet these same drugs can damage the DNA inside blood-making cells. This creates a difficult puzzle: how does the body recover from the initial immune crisis without falling into a new trap? Researchers in Iran recently examined two young patients who survived the initial crisis only to face a different, unexpected threat. Their story reveals how a single genetic flaw can set off a chain of events leading to two very different types of blood cancer, highlighting the complex and often unpredictable relationship between inherited disease, chronic inflammation, and medical treatment.

The story begins with two children who arrived at the hospital in the throes of a severe immune crisis. The first was a nine-year-old girl who had been suffering from persistent fevers, extreme tiredness, and a swollen spleen. Blood tests showed her body was in a state of high alert, with markers of inflammation soaring and her blood cell counts crashing. A look at her blood under a microscope revealed the telltale sign of Chediak–Higashi syndrome: white blood cells filled with giant, abnormal granules. Genetic testing confirmed the diagnosis, identifying a specific broken gene that prevented her cells from moving their internal cargo correctly. She was treated with a regimen designed to stop the immune overreaction, using a drug called etoposide to suppress the dangerous cells and steroids to reduce inflammation. For a time, the treatment worked. Her fever broke, her spleen shrank, and her blood counts began to recover.

However, the relief was not permanent. Several months after finishing her treatment, the girl's blood counts began to drop again. This time, the signs of a raging immune storm were missing, but her bone marrow was failing. When doctors examined the marrow, they found it was packed with immature cells called blasts, which had taken over the factory that makes healthy blood. This was not a return of the original immune disorder, but a new disease: acute myeloid leukemia. The cells in her marrow had changed their identity, becoming cancerous. Genetic tests showed that her leukemia did not carry the specific markers found in the most common forms of the disease, but it was clearly a distinct, aggressive cancer. The doctors realized that while the initial treatment had saved her life from the immune crisis, the combination of her inherited genetic flaw, years of chronic inflammation, and the exposure to the chemotherapy drug had created a perfect storm for this new malignancy to emerge.

The second patient was an infant boy who arrived at just eight months old with similar symptoms of fever and a swollen liver and spleen. Like the girl, his blood cells showed the characteristic giant granules, and genetic testing confirmed he also had Chediak–Higashi syndrome. He was treated with the same standard protocol of etoposide and steroids. He responded well, and for several years, he remained stable. But in 2023, four years after his first diagnosis, he fell ill again. His spleen grew large, and his blood markers indicated that the immune system was once again out of control. Doctors performed another bone marrow test to see if this was just a return of the original inflammation or something worse.

The results were startling. The marrow was filled with a specific type of immature cell known as a promyelocyte, which was behaving differently than the cells in the first patient. Further testing revealed that these cells carried a specific genetic fusion, a rearrangement of two genes that acts as a master switch for a particular type of blood cancer called acute promyelocytic leukemia. This is a distinct form of the disease, different from the leukemia seen in the first girl, and it is driven by a specific molecular error that was not present in the original syndrome. The boy was started on a treatment specifically designed for this type of leukemia. Unfortunately, his condition deteriorated rapidly. He developed severe complications, including a suspected infection and liver failure, and despite intensive care, he passed away.

These two cases, while tragic, offer a rare and clear window into how genetic diseases can evolve. Both children had the same underlying genetic defect and survived the same initial immune crisis, yet they developed two completely different types of blood cancer. One developed a leukemia with no specific genetic markers, while the other developed a leukemia defined by a specific gene fusion. This divergence suggests that the path to cancer in these patients is not a single, predictable road. Instead, it appears to be a complex interplay where the inherited genetic flaw sets the stage, the long-term stress of chronic inflammation adds pressure, and the necessary medical treatments may provide the final push that triggers a cancerous change.

The researchers emphasize that this outcome is exceptionally rare. While it is known that the drug used to treat the initial crisis can sometimes cause leukemia, it is unusual for two patients with the same genetic background to develop such different forms of the disease. The study suggests that the body's struggle to repair itself after years of immune chaos and medical intervention can lead to unpredictable results. The presence of the giant granules inside the cancer cells themselves serves as a reminder of the patient's original condition, yet the cancer cells have taken on a life of their own, driven by new and different errors.

This work does not claim to have solved the mystery of why these cancers happen, nor does it suggest that the treatment should be stopped. Instead, it highlights the need for doctors to remain vigilant. When a child with this syndrome survives the initial immune crisis but then develops new, unexplained problems with their blood counts, it may not be a simple relapse of the original disease. It could be the beginning of a new, distinct cancer. The authors propose that careful, long-term monitoring of the bone marrow in these patients is essential to catch these changes early. By understanding that the same starting point can lead to very different endings, medical science can better prepare for the complex journey these patients face, ensuring that the fight against one disease does not leave them vulnerable to another.